Amlodipine/rosuvastatin - Alvogen Korea

Drug Profile

Amlodipine/rosuvastatin - Alvogen Korea

Alternative Names: C1 R212+C2 R212; C1-R212/C2-R212; DP-R212

Latest Information Update: 14 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alvogen Korea
  • Class Antihypertensives; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hyperlipidaemia; Hypertension

Most Recent Events

  • 01 Jun 2017 Alvogen Korea withdraws prior to enrolment a phase III trial for Hypertension and Hypercholesterolaemia in South Korea (PO) (NCT02955368)
  • 11 Nov 2016 Chemical structure information added
  • 03 Nov 2016 Alvogen Korea plans a phase III trial for Hypertension and Hypercholesterolaemia in South Korea (PO) (NCT02955368)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top